DOCK2 modulates immune checkpoint inhibitor responsiveness and prognosis in cutaneous melanoma through multi-omics and single-cell T cell dynamics profiling

Abstract Background: Skin cutaneous melanoma (SKCM) is a highly aggressive malignancy that arises from melanocytes and has been associated with a notable increase in incidence and mortality rates across the globe. The current treatment modalities for SKCM, which encompass surgical interventions, radiotherapy, chemotherapy, and immunotherapy, have notably enhanced survival outcomes for certain patient subsets. Nonetheless, these approaches are frequently limited by factors such as variable efficacy, adverse side effects, and the emergence of resistance mechanisms. In this context, there is